There are currently 614 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
NCT06449352
Recruiting
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Westlake Eye Specialists - Austin Office, Austin, Texas
Conditions: Normal Tension Glaucoma
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Austin Research Center for Retina ., Austin, Texas
Conditions: Age-Related Macular Degeneration
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Austin, Texas
Conditions: Neoplasms
Register for Updates
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706
Recruiting
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: NEXT Austin, Austin, Texas
Conditions: Metastatic Solid Tumor
Register for Updates
Weighted Blanket to Treat Anxiety Related to Trying New Foods the Pediatric Population
NCT06420232
Recruiting
This small experimental pilot study addresses the knowledge gap related to the use of weighted blankets for children with anxiety related to food and eating.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/05/2024
Locations: Capital Area Speech & Occupational Therapy, Austin, Texas
Conditions: Food Neophobia, Picky Eating, Avoidant Restrictive Food Intake Disorder, Anxiety State
Register for Updates
A Just-in-Time Adaptive Intervention for Child and Family Mental Health
NCT06443918
Recruiting
The goal of this clinical trial is to test an app-based just-in-time-adaptive intervention (JITAI). The intervention aims to improve child and family mental health. A JITAI provides in-the-moment feedback to coach families. The questions it tests are if the app will improve mental health and family functioning. Participants will download an app on their phone and complete JITAI sessions. Researchers will compare intervention and control groups to see if the app improves mental health.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
05/30/2024
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Mental Health and Well-being, Family Functioning
Register for Updates
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897
Recruiting
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/29/2024
Locations: Sarah Cannon Research Institute at St. David's South Austin, Austin, Texas
Conditions: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
Register for Updates
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
Recruiting
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
05/28/2024
Locations: Texan Eye / Keystone Research, Austin, Texas
Conditions: Primary Open Angle Glaucoma
Register for Updates
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
NCT05954767
Recruiting
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: St. David's Surgical Hospital, Austin, Texas
Conditions: Ureter Injury
Register for Updates
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Recruiting
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
05/22/2024
Locations: St. David's South Austin Medical Center, Austin, Texas
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Register for Updates
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
NCT04160000
Recruiting
Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control has not been studied in this population. Catheter ablation and antiarrhythmic drugs are rhythm control therapies that have been used for treatment of AF without HF or HF with reduced systolic function but have not been widely ap... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: TCAI at St. David's Hospital, Austin, Texas
Conditions: Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Register for Updates
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
NCT05254405
Recruiting
Open-label study of brexanolone infusion for the treatment of posttraumatic stress disorder in 20 adult women with PTSD. Primary Objective: To determine if brexanolone injection infused intravenously for 24 hours at up to 60 μg/kg/h reduces PTSD symptom severity in a group of non-veteran adult female subjects diagnosed with PTSD as assessed by the change from baseline in the PTSD Checklist for DSM-5 (PCL-5) total score and rate of remission at 12-weeks post infusion. Secondary Objectives * T... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/21/2024
Locations: University of Texas at Austin Dell Medical School, Austin, Texas
Conditions: Post-Traumatic Stress Disorder
Register for Updates